$185 Million is the total value of Aisling Capital Management LP's 21 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | $61,591,000 | -39.1% | 6,068,125 | 0.0% | 33.24% | -6.9% | |
| GLUE | Monte Rosa Therapeutics Inc. (GLUE) | $20,642,000 | -31.3% | 1,472,331 | 0.0% | 11.14% | +5.0% | |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $17,815,000 | -20.6% | 1,025,000 | 0.0% | 9.61% | +21.5% | |
| HRMY | Sell | Harmony Biosciences Holdings Inc. (HRMY) | $16,678,000 | +10.0% | 342,815 | -3.5% | 9.00% | +68.3% |
| NUVB | Nuvation Bio Inc. (NUVB) | $13,366,000 | -38.1% | 2,541,009 | 0.0% | 7.21% | -5.3% | |
| ACRS | Aclaris Theraputics Inc. (ACRS) | $10,938,000 | +18.6% | 634,455 | 0.0% | 5.90% | +81.4% | |
| ELEV | Elevation Oncology Inc. (ELEV) | $7,144,000 | -58.1% | 2,834,910 | 0.0% | 3.86% | -36.0% | |
| TALS | Talaris Therapeutics Inc. (TALS) | $6,720,000 | -35.6% | 682,923 | 0.0% | 3.63% | -1.6% | |
| VRNA | Verona Pharma plc (VRNA)sponsored ads | $6,649,000 | -25.7% | 1,332,485 | 0.0% | 3.59% | +13.6% | |
| PSTX | Poseida Therapeutics Inc. (PSTX) | $4,674,000 | -34.2% | 1,043,267 | 0.0% | 2.52% | +0.6% | |
| AGLE | Aeglea Biotherapeutics Inc. (AGLE) | $3,890,000 | -51.6% | 1,691,151 | 0.0% | 2.10% | -25.9% | |
| BMEA | Biomea Fusion Inc. (BMEA) | $3,562,000 | -40.1% | 798,757 | 0.0% | 1.92% | -8.4% | |
| RPHM | Reneo Pharmaceuticals Inc. (RPHM) | $2,605,000 | -65.6% | 886,075 | 0.0% | 1.41% | -47.4% | |
| SPRB | Spruce Biosciences, Inc. (SPRB) | $2,423,000 | -54.9% | 1,205,511 | 0.0% | 1.31% | -31.0% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $1,383,000 | -53.7% | 3,142,857 | 0.0% | 0.75% | -29.2% | |
| VIRX | Viracta Therapeutics Inc. (VIRX) | $1,374,000 | +30.5% | 288,571 | 0.0% | 0.74% | +99.7% | |
| AVRO | AVROBIO, Inc. (AVRO) | $1,333,000 | -65.7% | 1,009,779 | 0.0% | 0.72% | -47.6% | |
| BCEL | Atreca Inc. (BCEL) | $1,229,000 | +4.6% | 387,653 | 0.0% | 0.66% | +59.8% | |
| ZSAN | Zosano Pharma Corporation (ZSAN) | $612,000 | -52.1% | 2,718,226 | 0.0% | 0.33% | -26.8% | |
| OBSV | Sell | ObsEva SA (OBSV) | $596,000 | -78.4% | 394,838 | -71.5% | 0.32% | -66.9% |
| Nabriva Therapeutics plc (NBRV) | $80,000 | -29.8% | 191,028 | 0.0% | 0.04% | +7.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.